Search Results - "Schroeder, Willibald"

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group by SEHOULI, Jalid, STENGEL, Dirk, NUGENT, Andreas, WILKE, Jochen, KUZNIK, Andreas, DOERING, Gabriele, WISCHNIK, Arthur, SOMMER, Harald, MEERPOHL, Hans-Gerd, SCHROEDER, Willibald, LICHTENEGGER, Werner, OSKAY-OEZCELIK, Guelten, HARTER, Philipp, KURZEDER, Christian, BELAU, Antje, BOGENRIEDER, Thomas, MARKMANN, Susanne, MAHNER, Sven, MUELLER, Lothar, LORENZ, Ralf

“…Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with…”
Get full text

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens by DU BOIS, Andreas, WEBER, Beatrice, RICHTER, Barbara, LUECK, Hans-Joachim, PFISTERER, Jacobus, COSTA, Serban, SCHROEDER, Willibald, KIMMIG, Rainer, PUJADE-LAURAINE, Eric, ROCHON, Justine, MEIER, Werner, GOUPIL, Alain, OLBRICHT, Sigrid, BARATS, Jean-Claude, KUHN, Walther, ORFEUVRE, Hubert, WAGNER, Uwe

“…Despite the progress that has been achieved, long-term survival rates in patients with advanced ovarian cancer are still disappointing. One attempt to improve…”
Get full text

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes by Kommoss, Stefan, Winterhoff, Boris, Oberg, Ann L, Konecny, Gottfried E, Wang, Chen, Riska, Shaun M, Fan, Jian-Bing, Maurer, Matthew J, April, Craig, Shridhar, Viji, Kommoss, Friedrich, du Bois, Andreas, Hilpert, Felix, Mahner, Sven, Baumann, Klaus, Schroeder, Willibald, Burges, Alexander, Canzler, Ulrich, Chien, Jeremy, Embleton, Andrew C, Parmar, Mahesh, Kaplan, Richard, Perren, Timothy, Hartmann, Lynn C, Goode, Ellen L, Dowdy, Sean C, Pfisterer, Jacobus

“…Recent progress in understanding the molecular biology of epithelial ovarian cancer has not yet translated into individualized treatment for these women or…”
Get full text

Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study by Slama, Jiri, Runnebaum, Ingo Bernard, Scambia, Giovanni, Angeles, Martina Aida, Bahrehmand, Kiarash, Kommoss, Stefan, Fagotti, Anna, Narducci, Fabrice, Matylevich, Olga, Holly, Jessica, Martinelli, Fabio, Koual, Meriem, Kopetskyi, Viacheslav, El-Balat, Ahmed, Corrado, Giacomo, Căpîlna, Mihai Emil, Schröder, Willibald, Novàk, Zoltán, Shushkevich, Alexander, Fricová, Lenka, Cibula, David

“…Fertility-sparing treatment in patients with cervical cancer should, in principle, follow identical algorithms to that in patients without future reproductive…”
Get full text

Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group by DU BOIS, Andreas, EWALD-RIEGLER, Nina, BURGES, Alexander, MEIER, Werner, HILLEMANNS, Peter, HANKER, Lars, HASENBURG, Annette, STRAUSS, Hans-Georg, HELLRIEGEL, Martin, WIMBERGER, Pauline, KEYVER-PAIK, Mignon-Denise, BAUMANN, Klaus, DE GREGORIO, Nikolaus, CANZLER, Ulrich, WOLLSCHLAEGER, Kerstin, FORNER, Dirk, PFISTERER, Jacobus, SCHRÖDER, Willibald, MÜNSTEDT, Karsten, RICHTER, Barbara, KOMMOSS, Stefan, HAUPTMANN, Steffen, REUSS, Alexander, MAHNER, Sven, FOTOPOULOU, Christina, KOMMOSS, Friedrich, SCHMALFELDT, Barbara, HILPERT, Felix, FEHM, Tanja

“…Borderline ovarian tumours (BOTs) are recognised as a unique entity of ovarian tumours that do not exert infiltrative destructive growth or stromal invasion…”
Get full text

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial by Pfisterer, Jacobus, Joly, Florence, Kristensen, Gunnar, Rau, Joern, Mahner, Sven, Pautier, Patricia, El-Balat, Ahmed, Kurtz, Jean-Emmanuel, Canzler, Ulrich, Sehouli, Jalid, Heubner, Martin L, Hartkopf, Andreas D, Baumann, Klaus, Hasenburg, Annette, Hanker, Lars C, Belau, Antje, Schmalfeldt, Barbara, Denschlag, Dominik, Park-Simon, Tjoung-Won, Selle, Frédéric, Jackisch, Christian, Burges, Alexander, Lück, Hans-Joachim, Emons, Günter, Meier, Werner, Gropp-Meier, Martina, Schröder, Willibald, de Gregorio, Nikolaus, Hilpert, Felix, Harter, Philipp

“…To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV…”
Get full text

Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7 by Heublein, Sabine, Pfisterer, Jacobus, du Bois, Andreas, Anglesio, Michael, Aminossadati, Behnaz, Bhatti, Irfan, Sehouli, Jalid, Wimberger, Pauline, Schochter, Fabienne, Hilpert, Felix, Hillemanns, Peter, Kalder, Matthias, Schroeder, Willibald, Mahner, Sven, Burges, Alexander, Canzler, Ulrich, Gropp-Meier, Martina, Jackisch, Christian, Harter, Philipp, Kommoss, Stefan, Marmé, Frederik

“…With more novel drugs being approved for the treatment of ovarian carcinoma, the question remains to what extent patients benefit from antiangiogenic treatment…”
Get full text

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8) by Emons, Günter, Kurzeder, Christian, Schmalfeldt, Barbara, Neuser, Petra, de Gregorio, Nikolaus, Pfisterer, Jacobus, Park-Simon, Tjoung-Won, Mahner, Sven, Schröder, Willibald, Lück, Hans-Joachim, Heubner, Martin Leonhard, Hanker, Lars, Thiel, Falk, Hilpert, Felix

“…Abstract Objectives To evaluate activity and toxicity of mTOR inhibitor temsirolimus in patients with platinum-refractory/resistant ovarian cancer (OC) or…”
Get full text

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial by Harter, Philipp, du Bois, Andreas, Hahmann, Maik, Hasenburg, Annette, Burges, Alexander, Loibl, Sibylle, Gropp, Martina, Huober, Jens, Fink, Daniel, Schröder, Willibald, Muenstedt, Karsten, Schmalfeldt, Barbara, Emons, Guenter, Pfisterer, Jacobus, Wollschlaeger, Kerstin, Meerpohl, Hans-Gerd, Breitbach, Georg-Peter, Tanner, Berno, Sehouli, Jalid

“…The role of cytoreductive surgery in relapsed ovarian cancer is not clearly defined. Therefore, patient selection remains arbitrary and depends on the center's…”
Get full text

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab by Kommoss, Stefan, Heitz, Florian, Winterhoff, Boris J. N., Wang, Chen, Sehouli, Jalid, Aliferis, Constantin, Kimmig, Rainer, Wang, Jinhua, Ma, Sisi, de Gregorio, Nikolaus, Mahner, Sven, Du Bois, Andreas, Tourani, Roshan, Park-Simon, Tjoung-Won, Baumann, Klaus, Taran, Florin Andrei, Kommoss, Friedrich, Schroeder, Willibald, Dowdy, Sean Christopher, Pfisterer, Jacobus

“…Abstract only…”
Get full text

Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study by Woelber, Linn, Hampl, Monika, Eulenburg, Christine Zu, Prieske, Katharina, Hambrecht, Johanna, Fuerst, Sophie, Klapdor, Ruediger, Heublein, Sabine, Gass, Paul, Rohner, Annika, Canzler, Ulrich, Becker, Sven, Bommert, Mareike, Bauerschlag, Dirk, Denecke, Agnieszka, Hanker, Lars, Runnebaumn, Ingo, Forner, Dirk M, Schochter, Fabienne, Klar, Maximilian, Schwab, Roxana, Koepke, Melitta, Kalder, Matthias, Hantschmann, Peer, Ratiu, Dominik, Denschlag, Dominik, Schroeder, Willibald, Tuschy, Benjamin, Baumann, Klaus, Mustea, Alexander, Soergel, Philipp, Bronger, Holger, Bauerschmitz, Gerd, Kosse, Jens, Koch, Martin C, Ignatov, Atanas, Sehouli, Jalid, Dannecker, Christian, Mahner, Sven, Jaeger, Anna

“…The need for pelvic treatment in patients with node-positive vulvar cancer (VSCC) and the value of pelvic lymphadenectomy (LAE) as a staging procedure to plan…”
Get full text

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO by Pfisterer, Jacobus, Weber, Béatrice, Reuss, Alexander, Kimmig, Rainer, du Bois, Andreas, Wagner, Uwe, Bourgeois, Hugues, Meier, Werner, Costa, Serban, Blohmer, Jens-Uwe, Lortholary, Alain, Olbricht, Sigrid, Stähle, Anne, Jackisch, Christian, Hardy-Bessard, Anne-Claire, Möbus, Volker, Quaas, Jens, Richter, Barbara, Schröder, Willibald, Geay, Jean-François, Lück, Hans-Joachim, Kuhn, Walther, Meden, Harald, Nitz, Ulrike, Pujade-Lauraine, Eric

“…Background: The combination of carboplatin and paclitaxel is the standard of care for the treatment of ovarian cancer, yet rates of recurrence and death remain…”
Get full text

Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease by Ramachandran, Dhanya, Tyrer, Jonathan P., Kommoss, Stefan, DeFazio, Anna, Riggan, Marjorie J., Webb, Penelope M., Fasching, Peter A., Lambrechts, Diether, García, María J., Rodríguez-Antona, Cristina, Goodman, Marc T., Modugno, Francesmary, Moysich, Kirsten B., Karlan, Beth Y., Lester, Jenny, Kjaer, Susanne K., Jensen, Allan, Høgdall, Estrid, Goode, Ellen L., Cliby, William A., Kumar, Amanika, Wang, Chen, Cunningham, Julie M., Winham, Stacey J., Monteiro, Alvaro N., Schildkraut, Joellen M., Cramer, Daniel W., Terry, Kathryn L., Titus, Linda, Bjorge, Line, Thomsen, Liv Cecilie Vestrheim, Pejovic, Tanja, Høgdall, Claus K., McNeish, Iain A., May, Taymaa, Huntsman, David G., Pfisterer, Jacobus, Canzler, Ulrich, Park-Simon, Tjoung-Won, Schröder, Willibald, Belau, Antje, Hanker, Lars, Harter, Philipp, Sehouli, Jalid, Kimmig, Rainer, de Gregorio, Nikolaus, Schmalfeldt, Barbara, Baumann, Klaus, Hilpert, Felix, Burges, Alexander, Winterhoff, Boris, Schürmann, Peter, Speith, Lisa-Marie, Hillemanns, Peter, Berchuck, Andrew, Johnatty, Sharon E., Ramus, Susan J., Chenevix-Trench, Georgia, Pharoah, Paul D. P., Dörk, Thilo, Heitz, Florian

“…Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705…”
Get full text

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB–IV by Meier, Werner, du Bois, Andreas, Rau, Jörn, Gropp-Meier, Martina, Baumann, Klaus, Huober, Jens, Wollschlaeger, Kerstin, Kreienberg, Rolf, Canzler, Ulrich, Schmalfeldt, Barbara, Wimberger, Pauline, Richter, Barbara, Schröder, Willibald, Belau, Antje, Stähle, Anne, Burges, Alexander, Sehouli, Jalid

“…Abstract Objectives This study evaluates whether a molecular targeted therapy with the farnesyltransferase inhibitor lonafarnib added to standard chemotherapy…”
Get full text

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7) by Harter, Philipp, Sehouli, Jalid, Reuss, Alexander, Baumann, Klaus, Hanker, Lars, Kimmig, Rainer, Schröder, Willibald, Burges, Alexander, Gropp-Meier, Martina, Kurzeder, Christian, Mahner, Sven, Canzler, Ulrich, Lück, Hans-Joachim, Meier, Werner, Fehm, Tanja, du Bois, Andreas

“…Gynecologic sarcomas are rare diseases with still undefined optimal treatment. Platinum and anthracyclines were reported as active agents in gynecologic…”
Get more information

Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: A multicenter phase II trial of the AGO Study Group (AGO-GYN 8) by Emons, Guenter, Kurzeder, Christian, Schmalfeldt, Barbara, Reuss, Alexander, de Gregorio, Nikolaus, Pfisterer, Jacobus, Park-Simon, Tjoung-Won, Mahner, Sven, Schroeder, Willibald, Lueck, Hans-Joachim, Heubner, Martin Leonhard, Hanker, Lars Christian, Thiel, Falk, Hilpert, Felix

“…Abstract only…”
Get full text

What is the evidence for lymphadenectomy in presumed early ovarian cancer? by Schmalfeldt, Barbara, Brambs, Christine, Burges, Alexander, El-Balat, Ahmed, Emons, Günter, Fink, Daniel, Fotopoulou, Christina, Gropp-Meier, Martina, Hanker, Lars-Christian, Harter, Philipp, Hasenburg, Annette, Hauptmann, Steffen, Hilpert, Felix, Kimmig, Rainer, Kommoss, Stefan, Kurzeder, Christian, Mahner, Sven, Marmé, Frederik, Mayr, Doris, Meier, Werner, Meinhold-Heerlein, Ivo, Mustea, Alexander, Ortmann, Olaf, Oskay-Özcelik, Gülten, Pfisterer, Jacobus, Pölcher, Martin, Runnebaum, Ingo B., Schröder, Willibald, Tanner, Berno, Wagner, Uwe, Wimberger, Pauline, Sehouli, Jalid

Get full text

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study by Fotopoulou, Christina, Sehouli, Jalid, Ewald-Riegler, Nina, de Gregorio, Nikolaus, Reuss, Alexander, Richter, Rolf, Mahner, Sven, Kommoss, Friedrich, Schmalfeldt, Barbara, Fehm, Tanja, Hanker, Lars, Wimberger, Pauline, Canzler, Ulrich, Pfisterer, Jacobus, Kommoss, Stefan, Hauptmann, Steffen, du Bois, Andreas

“…The value of the serum tumor marker CA125 in borderline tumors of the ovary (BOTs) is not well defined, with unclear benefit in both diagnosis and follow-up…”
Get more information

Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study by De Gregorio, Nikolaus, Baumann, Klaus H., Keyver-Paik, Mignon-Denise, Reuss, Alexander, Canzler, Ulrich, Wollschlaeger, Kerstin, Kommoss, Friedrich, Forner, Dirk, Peters, Martin, Schroeder, Willibald, Münstedt, Karsten, Richter, Barbara, Ewald-Riegler, Nina, Mahner, Sven, Fotopoulou, Christina, Schmalfeldt, Barbara, Hilpert, Felix, Kommoss, Stefan, Hauptmann, Steffen, Du Bois, Andreas

“…Abstract only 5005 Background: Borderline ovarian tumors (BOT) are a rare entity; current standard of care is based on the available data of predominantly…”
Get full text

Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer by Schroeder, W, Biesterfeld, S, Zillessen, S, Rath, W

“…Epidermal growth factor receptor is considered to play an important role in the carcinogenesis and progression of breast cancer, but its clinical significance…”
Get more information